Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jeffm34on Oct 13, 2021 7:54pm
167 Views
Post# 34003375

RE:RE:RE:I have complaints

RE:RE:RE:I have complaints

That was my first thought when I heard China come up. Look no further than the Canadian governments deal with Cansino to produce a Covid vaccine.  Nothing positive can come out of a deal with a Chinese company.

https://healthydebate.ca/2020/10/about-healthy-debate/opinions-about-healthy-debate/canadas-failed-vaccine-partnership/


SPCEO1 wrote:

7.) China??? If they do a deal with China we should fully expect the Chinese partner to steal whatever IP they can get their hands on. Any such partnership is not likely to end well. The evidence is overwhelming that the risk in any such partnership with the Chinese is great. Just ask the Evergrande foreign bond holders or Jack Ma or any number of others businesses in China that are currently getting hammered by President Xi's whims. I wonder why we don't see a lot of major pharma companies doing deals with the Chinese? I hope our CEO does not end up making a rookie mistake with China. 

OK, I have got that out of my system now. But it really was a great call with regard to cancer and if TH can keep from messing it up, the liklihood of very meaningful upside on the stock now seems even more assured than previously. 

 

<< Previous
Bullboard Posts
Next >>